Immuron Plans Phase 2 Trial for IMM-529 following FDA review

Stock Information for NCS Multistage Holdings Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About NCS Multistage Holdings Inc.

Immuron CEO, Steven Lydeamore participation in Maxim Virtual Healthcare Conference
Immuron Travelan® continued strong sales growth
NMRC Reports Results for Campylobacter Controlled Human Infection Model Study
Presenting on the Emerging Growth Conference 75 Day 1 on September 25 Register Now
Presenting on the Emerging Growth Conference 74 Day 2 on August 22 Register Now
Immuron Announces New U.S. Department of Defense Research Award for Naval Medical Research Command and Walter Reed Army Institute of Research to advance Travelan®
Immuron CEO, Steven Lydeamore to present at the Emerging Growth Conference
Immuron CEO, Steven Lydeamore to host webinar on MarketOpen Direct Connect

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.